PFIZER INC (PFE): Results of Operations and Financial Condition
PFIZER INC (PFE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99 Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance ■ Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products (1) ■ Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Nex
How this was made
The 30-second read
Why it matters
The key tradable signal is the raised 2026 revenue guidance midpoint by $500 million, while adjusted diluted EPS guidance is reaffirmed in the $2.80 to $3.00 range with an approximately $0.10 transaction-related absorption.
Market read
A guidance raise with quantified revenue and EPS framework is a direct catalyst for re-pricing Pfizer’s 2026 fundamentals and near-term expectations.
What to watch
Investors may focus on the timing of the Innovent Biologics acquired in-process R&D charge to be recorded in Q3 2026, which could pressure reported earnings even if adjusted metrics remain guided.
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
Revenue increased 3% and 1% operationally, supported by 18% operational growth in launched and acquired products, but reported results moved to a loss because of $4.3 billion in non-cash intangible asset impairments. Pfizer raised the midpoint of full-year revenue guidance while reaffirming adjusted diluted EPS guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Second-Quarter RevenuesGAAP | $15,034 million | – | 3%; 1% operationally |
| Second-Quarter Reported Net Income/(Loss)GAAP | $(248) million | – | – |
| Second-Quarter Reported Diluted EPS/(LPS)GAAP | $(0.04) | – | – |
| Second-Quarter Adjusted Incomenon-GAAP | $4,440 million | – | —% |
| Second-Quarter Adjusted Diluted EPSnon-GAAP | $0.77 | – | —% |
| Second-Quarter Cost of SalesGAAP | $4,092 million | – | 8%; 7% operationally |
| Second-Quarter Cost of Sales as Percent of RevenuesGAAP | 27.2 % | – | – |
| Second-Quarter SI&A ExpensesGAAP | $3,411 million | – | —%; (1%) operationally |
| Second-Quarter R&D ExpensesGAAP | $2,809 million | – | 13%; 13% operationally |
| Second-Quarter Acquired IPR&D ExpensesGAAP | $16 million | – | *; * operationally |
| Second-Quarter Other (Income)/Deductions—netGAAP | $3,716 million | – | *; * operationally |
| Second-Quarter Effective Tax Rate on Reported Income/(Loss)GAAP | 62.4 % | – | – |
| Six Months RevenuesGAAP | $29,484 million | – | 4% |
| Six Months Reported Net Income/(Loss)GAAP | $2,440 million | – | (58%) |
| Six Months Reported Diluted EPS/(LPS)GAAP | $0.43 | – | (59%) |
| Six Months Adjusted Incomenon-GAAP | $8,730 million | – | (10%) |
| Six Months Adjusted Diluted EPSnon-GAAP | $1.52 | – | (10%) |
| Six Months Cost of SalesGAAP | $7,640 million | – | 15%; 10% operationally |
| Six Months Cost of Sales as Percent of RevenuesGAAP | 25.9 % | – | – |
| Six Months SI&A ExpensesGAAP | $6,372 million | – | (1%); (3%) operationally |
| Six Months R&D ExpensesGAAP | $5,299 million | – | 13%; 12% operationally |
| Six Months Acquired IPR&D ExpensesGAAP | $153 million | – | *; * operationally |
| Six Months Other (Income)/Deductions—netGAAP | $4,577 million | – | *; * operationally |
| Six Months Effective Tax Rate on Reported Income/(Loss)GAAP | 2.1 % | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Global Biopharmaceuticals Business (Biopharma)The quarterly operational increase was driven by Eliquis, Padcev, the Vyndaqel family, Lorbrena and several other products across categories, partially offset by lower COVID-19 product revenues and several other products across categories. | $14,661 million | – | 2% total; 1% operationally |
| Pfizer CentreOneNo specific driver was provided. | $373 million | – | 7% total; 5% operationally |
Full-Year 2026 outlook
- Revenue$60.5 to $62.5 billion
- Tax rate~15.0%
- NoteAdjusted (3) SI&A Expenses: $12.5 to $13.5 billion
- NoteAdjusted (3) R&D Expenses: $10.5 to $11.5 billion
- NoteAdjusted (3) Diluted EPS: $2.80 to $3.00
- NoteCOVID-19 products: approximately $4 billion
- Note$650 million Acquired In-Process R&D charge related to the completed licensing agreement with Innovent Biologics, Inc. that will be recorded in the third quarter of 2026 with an expected unfavorable impact of approximately $0.10
Capital returns
- $4.9 billion of cash dividends during the first six months of 2026
- $0.86 per share of common stock
- No share repurchases have been completed to date in 2026.
- As of August 4, 2026, Pfizer’s remaining share repurchase authorization is $3.3 billion.
- Current financial guidance does not anticipate any share repurchases in 2026.
What drove it
- Second-quarter revenues excluding contributions from Comirnaty and Paxlovid grew 5% operationally.
- Second-quarter revenues of launched and acquired products grew 18% operationally.
- Eliquis was up 19% operationally, driven primarily by higher U.S. net price, including lower rebates and channel mix favorability, as well as higher global demand.
- Padcev was up 23% operationally, driven primarily by increased market share in first-line la/mUC and launch uptake in the cisplatin-ineligible indication for muscle-invasive bladder cancer.
- The Vyndaqel family was up 8% operationally, supported by international demand, continuing patient diagnosis uptake, improved access in certain international markets, and continued U.S. market expansion.
- Lorbrena was up 37% operationally, driven primarily by increased patient share in the first-line ALK+ mNSCLC treatment setting in the U.S., China, and certain other international markets.
- Pfizer announced additional anticipated productivity enhancement savings of $2.5 billion associated with ongoing initiatives, expected to be realized from 2027 through 2029.
Concerns
- Paxlovid revenue was down 95% operationally, driven primarily by lower COVID-19 infections and lower government purchases in certain international markets.
- Comirnaty revenue was down 34% operationally, driven primarily by a lower favorable adjustment to the returns provision and lower U.S. utilization following a narrower vaccination recommendation.
- Second-quarter reported loss per share reflects $4.3 billion in non-cash intangible asset impairments.
- Cost of Sales as a percentage of revenues increased by 1.4 percentage points, primarily due to unfavorable sales mix and higher amortization of the fair value step-up of acquired inventory, primarily driven by the Oxbryta impairment.
- R&D Expenses increased 13% operationally, driven primarily by higher spending in certain oncology and obesity product candidates.
- The updated EPS guidance absorbs an expected unfavorable impact of approximately $0.10 from the Innovent Biologics, Inc. transaction.
What to watch
- Performance of non-COVID products, which Pfizer said was better than expected by approximately $1.5 billion in its revised full-year revenue outlook.
- COVID-19 product revenue expectation of approximately $4 billion, revised from approximately $5 billion previously.
- The $650 million Acquired In-Process R&D charge related to the Innovent Biologics, Inc. licensing agreement expected in the third quarter of 2026.
- Execution of productivity enhancement initiatives and the additional anticipated savings of $2.5 billion expected from 2027 through 2029.
- Several key pivotal readouts expected over the next 12 months.
Balance sheet and cash flow
- $5.3 billion invested in internal research and development projects during the first six months of 2026
- Approximately $170 million invested in business development transactions during the first six months of 2026
- On July 10, 2026, Pfizer completed the Innovent Biologics, Inc. transaction, which will be recorded in the third quarter of 2026.
Analysis
Second-quarter revenue was $15,034 million, up 3% year over year and 1% operationally. The reported growth rate includes a favorable impact of foreign exchange of $217 million, while the operational increase of $164 million was driven by key non-COVID products. Excluding Comirnaty and Paxlovid, revenue grew 5% operationally, and launched and acquired products grew 18% operationally. Pfizer raised the midpoint of its full-year revenue guidance to $61.5 billion from $61.0 billion.
Product mix remains centered on growth brands. Eliquis, Padcev, the Vyndaqel family and Lorbrena each posted positive operational growth, with Lorbrena up 37% operationally and Padcev up 23% operationally. In contrast, Paxlovid declined 95% operationally and Comirnaty declined 34% operationally. Pfizer now expects approximately $4 billion in COVID-19 product revenue for 2026, down from approximately $5 billion previously, while citing better-than-expected non-COVID product performance of approximately $1.5 billion.
Profitability was materially affected by non-cash intangible asset impairments. Pfizer reported a second-quarter net loss of $(248) million and reported diluted LPS of $(0.04), versus reported net income of $2,910 million and diluted EPS of $0.51 in the prior-year quarter. Other (income)/deductions, net rose to $3,716 million from $739 million, primarily due to intangible asset impairment charges and, to a lesser extent, charges for certain legal matters. Adjusted income was broadly flat at $4,440 million, while adjusted diluted EPS was $0.77 compared with $0.78.
Cost pressure was evident in the reported cost of sales ratio, which rose to 27.2% of revenues from 25.8%, reflecting unfavorable sales mix and higher amortization of the fair value step-up of acquired inventory, primarily driven by the Oxbryta impairment. SI&A Expenses were essentially flat on a reported basis and declined 1% operationally, while R&D Expenses increased 13% operationally due to oncology and obesity product candidate spending. Pfizer also announced $2.5 billion of additional anticipated productivity enhancement savings expected from 2027 through 2029.
Capital deployment during the first six months included $5.3 billion in internal R&D, approximately $170 million in business development transactions and $4.9 billion of cash dividends. No share repurchases have been completed to date in 2026, and current guidance does not anticipate repurchases in 2026. The company reaffirmed adjusted diluted EPS guidance of $2.80 to $3.00, which absorbs a $650 million Acquired In-Process R&D charge to be recorded in the third quarter of 2026 and an expected unfavorable impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction.
Management, verbatim
Pfizer had another strong quarter, delivering on our financial commitments and advancing our strategy. Our launched and acquired products (1) performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength. I am confident we will create substantial future value for patients and shareholders.
Dr. Albert Bourla, Chairman and CEO of Pfizer
Our second-quarter results are attributable to our solid commercial performance globally as well as our ongoing focus on operational efficiency. This quarter, I’m particularly pleased with the 18% year-over-year operational revenue growth from our launched and acquired products (1) . Our updated full-year 2026 guidance reflects the continued strength of and confidence in our business.
Cecile Guegan, Incoming Interim CFO and EVP of Pfizer
Not in the filing
stated, not guessed- Period-end date
- Second-quarter gross margin
- Six-month gross margin
- Operating cash flow
- Free cash flow
- Cash balance
- Debt balance
- Product-level revenue amounts
- Segment prior-quarter revenue and quarter-over-quarter changes
- Full-year 2026 gross-margin guidance
- Full-year 2026 operating-expense guidance as a combined line item
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Pfizer’s SEC Form 8-K (Item 2.02) covering Q2 2026 results and full-year 2026 guidance updates, including cost productivity initiatives and the Innovent Biologics transaction accounting impact.
Ticker impact
Pfizer reported Q2 2026 results and raised full-year 2026 revenue guidance by $500 million at the midpoint to $60.5 to $62.5B.
Likely supportive for the stock on guidance optics, with follow-through dependent on how investors weigh the non-cash impairment and the upcoming Q3 Innovent-related charge.
The filing discloses a concrete guidance change (revenue midpoint +$0.5B) and specifies the EPS guidance is reaffirmed while absorbing an approximately $0.10 impact tied to the Innovent transaction.
Market effects
Large-cap pharma peers may see read-across on non-COVID product momentum and cost productivity initiatives.
Primarily US large-cap sentiment, with potential spillover to global pharma indices given Pfizer’s scale.
Guidance update can influence broader investor positioning toward late-stage pipeline and obesity/oncology narratives.
Counterpoint
Reported results include a large non-cash intangible impairment and adjusted EPS is unchanged, so the guidance raise may not translate into earnings upside.
Key entities
- companyPfizer Inc.
Reported Q2 2026 results and raised full-year 2026 revenue guidance by $500 million at the midpoint; reaffirmed adjusted diluted EPS guidance.
- companyInnovent Biologics, Inc.
Transaction-related acquired in-process R&D charge to be recorded in Q3 2026, with an expected unfavorable impact of approximately $0.10 on adjusted diluted EPS guidance.
